First participant dosed in Jade’s Phase II JUNIPER trial for IgAN

Jade Biosciences Doses First Participant in Phase II JUNIPER Trial for IgAN

Jade Biosciences has dosed the first participant in its open-label Phase II JUNIPER clinical trial, evaluating JADE101 for immunoglobulin A nephropathy (IgAN). The trial aims to enroll 30 participants to assess the antibody's safety, tolerability, and efficacy in this chronic autoimmune kidney disease. JADE101 is engineered to selectively block the cytokine A PRoliferation-Inducing Ligand (APRIL), which is regarded as a driver of pathogenic IgA production in IgAN. Interim data from the JUNIPER trial is expected in 2027.

• JADE101 is a fully human monoclonal antibody designed to block A PRoliferation-Inducing Ligand (APRIL) with ultra-high affinity. This mechanism aims to prevent the formation of high molecular weight immune complexes, targeting predictable pharmacokinetics and reducing immunogenicity risk, which is crucial for treating IgAN.
• The open-label Phase II JUNIPER trial will enroll 30 IgAN patients to evaluate JADE101's safety, tolerability, and efficacy. Investigators will specifically analyze changes in urine protein-to-creatinine ratio, a recognized prognostic marker, along with renal function determined by estimated glomerular filtration rate (eGFR), and resolution of haematuria.
• Preclinical data for JADE101 supports its potential to drive deep and sustained IgA reductions. Its pharmacokinetic and pharmacodynamic properties are designed to enable infrequent and convenient subcutaneous dosing, potentially no more frequently than every eight weeks, which is a significant advantage for young adults requiring lifelong treatment for IgAN.

Unraveling the Pathogenesis of IgA Nephropathy

The pathogenesis of IgA nephropathy involves complex genetic, molecular, and cellular mechanisms that collectively drive disease development and progression. At the molecular level, galactose-deficient IgA1 (Gd-IgA1) serves as a central disease driver in the multi-hit hypothesis, where abnormal O-glycosylation of the IgA1 molecule leads to formation of poorly galactosylated IgA1 O-glycoforms in both serum and mesangial deposits. These aberrant glycoforms act as autoantigens driving formation of glycan-specific antibodies or serve as antigens for cross-reactive antimicrobial antibodies, ultimately resulting in circulating and mesangial IgA-containing immune complexes that activate mesangial cells, induce podocyte injury, and activate proximal tubular epithelial cells. Additionally, IgA-type anti-mesangial cell antibodies (IgA-MESCA) have been identified that target specific mesangial cell-surface antigens β2-spectrin and CBX3, contributing to an autoimmune component in disease pathogenesis.

Genetic factors play a significant role in IgAN susceptibility, though known genetic variations explain only 11% of disease variation. Key genetic mechanisms include polymorphisms in Megsin (SERPINB7), predominantly expressed in glomerular mesangium, where specific alleles (2093C and 2180T) show significant transmission from heterozygous parents to affected patients. Copy number variants (CNVs) also contribute to pathogenesis, particularly a CNV on chromosome 3 containing the TLR9 gene, where patients with deteriorated renal function carry low copy numbers correlating with reduced TLR9 expression. Complement pathway genes are implicated, with complement factor H serving as a protective factor while complement factor H-related protein 1 acts as a risk factor. Shared susceptibility loci between IgAN and systemic lupus erythematosus have been identified, involving genes such as UBE2L3, FCGR2B, ANXA6, and BLK.

Cellular mechanisms center on the selective deposition of Gd-IgA1-containing immune complexes in the glomerular mesangial region, though debate continues whether this reflects passive trapping or active antibody-mediated deposition. The mesangial response to deposited IgA is critical, as genetic predisposition appears necessary for IgA deposition to trigger glomerulonephritis. Immune cell involvement includes causal associations with elevated neutrophil counts and specific T cell populations, while interstitial mast cell infiltration contributes to glomerulosclerosis and tubulointerstitial injury progression. Dysregulation of Wnt and TGF-β signaling pathways, along with inflammasome pathway activation involving PYDC1, caspase1, NLRP3, and IL1β, further drives disease progression through inflammatory mechanisms.

JADE101's Phase II Launch: Navigating the Evolving IgAN Landscape

The initiation of Jade Biosciences' Phase II JUNIPER trial for JADE101 marks a notable development in the ongoing quest to address IgA nephropathy (IgAN), a chronic autoimmune kidney disease that frequently leads to end-stage kidney disease. IgAN's complex pathogenesis, often described by the "four-hit hypothesis," involves the overproduction and deposition of pathogenic galactose-deficient IgA1 (Gd-IgA1) immune complexes in the glomeruli, driving inflammation and kidney damage. A Proliferation-Inducing Ligand (APRIL) has emerged as a pivotal upstream mediator in this process, playing a crucial role in B-cell activation, plasma cell survival, and IgA class switching, making it an attractive therapeutic target.

JADE101, as a selective APRIL blocker, enters a dynamic and increasingly competitive therapeutic arena. Several other anti-APRIL agents, including sibeprenlimab and zigakibart, and dual BAFF/APRIL inhibitors like atacicept, telitacicept, and povetacicept, are already in advanced clinical trials or have received initial approvals. These agents have demonstrated promising results in reducing proteinuria and stabilizing eGFR, aligning with the latest KDIGO guidelines that emphasize therapies preventing pathogenic IgA production. For JADE101, demonstrating a compelling efficacy profile, particularly in reducing proteinuria and Gd-IgA1 levels, alongside a favorable safety and tolerability profile, will be critical for differentiation. The selective nature of JADE101, targeting only APRIL, could potentially offer a cleaner safety profile compared to dual inhibitors that also block BAFF, which have shown broader immunoglobulin suppression in some studies. However, the long lead time for interim data, expected in 2027, presents a strategic challenge in a market where competitors are rapidly advancing. Jade Biosciences will need to articulate a clear value proposition for JADE101 to carve out its niche and ultimately offer a meaningful, disease-modifying option for patients living with IgAN.